Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alemtuzumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    99 result(s) found for: Alemtuzumab. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-000053-22 Sponsor Protocol Number: HM06/7328 Start Date*: 2006-05-30
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Eradication of Minimal Residual Disease (MRD) in patients with Chronic Lymphocytic Leukaemia (CLL) with Alemtuzumab: A Phase II Study
    Medical condition: Chronica Lymphocytic Leukaemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-010788-18 Sponsor Protocol Number: CAMMS03409 Start Date*: 2009-07-01
    Sponsor Name:Genzyme Corporation
    Full Title: An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) AT (Completed) PL (Completed) CZ (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021146-22 Sponsor Protocol Number: 5339 Start Date*: 2012-10-23
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Alemtuzumab and rheumatoid arthritis - an immunisation study
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003097-26 Sponsor Protocol Number: GELLC-2 Start Date*: 2007-12-22
    Sponsor Name:Francesc Bosch Albareda
    Full Title: Tratamiento de rescate con Rituximab-CHOP seguido de Alemtuzumab (R-CHOP-A) en pacientes con leucemia linfática crónica refractarios o racaidos tras tratamiento con análogos de las purinas.
    Medical condition: Tretamiento de rescate con Rituximab-CHOP seguido de Alemtuzumab en pacientes con elucemia linfática crónica refactarios o recaidos tras tratamiento con análogos de las purinas.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003884-71 Sponsor Protocol Number: LPS13649 Start Date*: 2015-02-05
    Sponsor Name:Genzyme Corporation
    Full Title: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017087-17 Sponsor Protocol Number: AL1.0 Start Date*: 2010-09-29
    Sponsor Name:Addenbrooke's Hospital
    Full Title: Alemtuzumab for ANCA-Associated Refractory Vasculitis - A study of safety and efficacy (ALEVIATE).
    Medical condition: ANCA-associated vasculitis (AAV)
    Disease: Version SOC Term Classification Code Term Level
    12 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006491-30 Sponsor Protocol Number: CHB 08 03 Start Date*: 2009-02-06
    Sponsor Name:Centre Henri Becquerel
    Full Title: Etude prospective, multicentrique, de phase II testant la faisabilité d’un traitement d’entretien par l’alemtuzumab chez des patients porteurs de leucémie lymphoïde chronique, traités et répondant ...
    Medical condition: Chronic lymphoid leukemia in complete remission (CR) or partial remission (PR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001421-34 Sponsor Protocol Number: TPLL2 Start Date*: 2009-12-07
    Sponsor Name:University of Cologne, Sponsor-Quality Management
    Full Title: Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Le...
    Medical condition: Untreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003100-30 Sponsor Protocol Number: EFC13429 Start Date*: 2017-04-04
    Sponsor Name:Genzyme Corporation
    Full Title: A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) NO (Completed) GR (Completed) PT (Completed) NL (Prematurely Ended) BE (Prematurely Ended) BG (Temporarily Halted) Outside EU/EEA FR (Ongoing) PL (Completed) AT (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000741-19 Sponsor Protocol Number: Fl SC ale (Full-Scale) Start Date*: 2007-07-04
    Sponsor Name:UHL NHS Trust
    Full Title: A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.
    Medical condition: Chronic Lymphocytic Leukaemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003012-35 Sponsor Protocol Number: HM07/8281 Start Date*: 2012-06-12
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CL...
    Medical condition: Chronic lymphocytic leukaemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002305-23 Sponsor Protocol Number: SM3 Start Date*: 2008-02-05
    Sponsor Name:R&D Addenbrookes Hospital
    Full Title: A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3.
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000464-42 Sponsor Protocol Number: ALEMLL08091 Start Date*: 2016-06-13
    Sponsor Name:Genzyme GmbH
    Full Title: A Prospective, Open-label, Interventional Phase IIIb Clinical Trial to Investigate the Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After ...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006163-31 Sponsor Protocol Number: Hx-CD20-406 Start Date*: 2006-05-16
    Sponsor Name:Genmab A/S
    Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alem...
    Medical condition: B-cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10008959 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) IT (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001161-14 Sponsor Protocol Number: CAMMS 323 Start Date*: 2007-08-24
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) SE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004987-37 Sponsor Protocol Number: CLL-6 Start Date*: 2010-01-21
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Bendamustine Combined with Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) – A Phase I/II Trial with Concomitant Evaluation of Safety and Efficacy
    Medical condition: Pre-treated chronic lymphocytic leukaemia (B-CLL)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001162-32 Sponsor Protocol Number: CAMMS 32400507 Start Date*: 2007-12-24
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) SE (Completed) DE (Completed) FR (Completed) BE (Completed) ES (Completed) CZ (Completed) AT (Completed) IT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024389-23 Sponsor Protocol Number: 114813 Start Date*: 2011-06-07
    Sponsor Name:Department of Hematology
    Full Title: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005275-18 Sponsor Protocol Number: HCT0022006 Start Date*: 2008-08-18
    Sponsor Name:Astellas
    Full Title: Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patient...
    Medical condition: Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patient...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 13:12:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA